OTCMKTS:GMXAY GENMAB A/S/S (GMXAY) Stock Price, News & Analysis $35.32 +0.49 (+1.41%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsOwnership About GENMAB A/S/S Stock (OTCMKTS:GMXAY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GENMAB A/S/S alerts:Sign Up Key Stats Today's Range$34.70▼$35.4750-Day Range$28.52▼$35.2252-Week Range$12.10▼$19.00Volume3.58 million shsAverage Volume48,553 shsMarket CapitalizationN/AP/E Ratio13.56Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing differentiated antibody therapeutics for the treatment of cancer and other serious diseases. The company’s research platform includes antibody technologies designed to engage the immune system, including its DuoBody technology for creating bispecific antibodies and HexaBody technology for enhancing antibody activity. Genmab’s medicines and partnered products include Darzalex (daratumumab) for multiple myeloma, Kesimpta (ofatumumab) for certain forms of multiple sclerosis, Epkinly or Tepkinly (epcoritamab) for B-cell lymphomas, and Tivdak (tisotumab vedotin) for cervical cancer. Several of these products were developed or commercialized through collaborations with larger pharmaceutical companies, including Johnson & Johnson, Novartis, AbbVie and Pfizer. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab serves international markets through its global research, development and commercial partnerships. The company is led by Chief Executive Officer Jan van de Winkel, who has been associated with Genmab since its early development and has served as CEO since 2010.AI Generated. May Contain Errors. Read More Receive GMXAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GENMAB A/S/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMXAY Stock News HeadlinesGenmab and AbbVie’s Epkinly combo improves PFS in second-line DLBCL trialJune 30, 2026 | msn.comGenmab A/S ADRApril 13, 2026 | barrons.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 27 at 1:00 AM | The Oxford Club (Ad)Genmab (GMAB) fuels confidence based on upcoming Epkinly and Petosemtamab readoutsMarch 26, 2026 | msn.comA Peek at Genmab's Future EarningsFebruary 16, 2026 | benzinga.comGenmab: Darzalex Growth Fuels Rally, Upside Is TightJanuary 23, 2026 | seekingalpha.comGenmab (GMAB)’s future potential underappreciated by marketJanuary 21, 2026 | msn.comGenmab completes acquisition of Merus NV to bolster oncology portfolioDecember 12, 2025 | msn.comSee More Headlines GMXAY Stock Analysis - Frequently Asked Questions How have GMXAY shares performed this year? GENMAB A/S/S's stock was trading at $33.42 at the beginning of 2026. Since then, GMXAY stock has increased by 5.7% and is now trading at $35.32. Who are GENMAB A/S/S's major shareholders? GENMAB A/S/S's top institutional investors include Madison Asset Management LLC. How do I buy shares of GENMAB A/S/S? Shares of GMXAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:GMXAY CIKN/A Webwww.genmab.com Phone45 70 20 27 28FaxN/AEmployees1,660Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio13.56 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:GMXAY) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENMAB A/S/S Please log in to your account or sign up in order to add this asset to your watchlist. Share GENMAB A/S/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
